Phase II study of CI-980 (NSC 635370) in patients with previously treated advanced soft-tissue sarcomas
- 1 March 1998
- journal article
- clinical trial
- Published by Springer Nature in Investigational New Drugs
- Vol. 16 (1) , 87-92
- https://doi.org/10.1023/a:1006078930550
Abstract
Doxorubicin and ifosfamide are the two most active agents in the treatment of soft-tissue sarcomas. Patients whose tumors have failed these two drugs have very limited systemic therapy options. It...Keywords
This publication has 10 references indexed in Scilit:
- High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.Journal of Clinical Oncology, 1997
- Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent.1997
- Cancer statistics, 1997CA: A Cancer Journal for Clinicians, 1997
- Inhibition of microtubules and cell cycle arrest by a new 1-deaza-7,8-dihydropteridine antitumor drug, CI 980, and by its chiral isomer, NSC 613863.1994
- ANTITUMOR-ACTIVITY OF ETHYL 5-AMINO-1,2-DIHYDRO-2-METHYL-3-PHENYLPYRIDO[3,4-B]PYRAZIN-7-YLCARBAMATE, 2-HYDROXYETHANESULFONATE, HYDRATE (NSC-370147) AGAINST SELECTED TUMOR SYSTEMS IN CULTURE AND IN MICE1990
- New anticancer agents: chiral isomers of ethyl 5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazine-7-carbamateJournal of Medicinal Chemistry, 1989
- COMPARISON OF 1,2-DIHYDROPYRIDO[3,4-B]PYRAZINES (1-DEAZA-7,8-DIHYDROPTERIDINES) WITH SEVERAL OTHER INHIBITORS OF MITOSIS1987
- BIOLOGICAL EFFECTS AND STRUCTURE-ACTIVITY-RELATIONSHIPS OF 1,2-DIHYDROPYRIDO[3,4-B]PYRAZINES1983
- INHIBITION OF MITOSIS AND ANTICANCER ACTIVITY AGAINST EXPERIMENTAL NEOPLASMS BY ETHYL 5-AMINO-1,2-DIHYDRO-3-[(N-METHYLANILINO)METHYL]-PYRIDO[3,4-B]PYRAZIN-7-YLCARBAMATE (NSC-181928)1982
- Dose response evaluation of adriamycin in human neoplasiaCancer, 1977